메뉴 건너뛰기




Volumn 95, Issue 1, 2012, Pages

The safety, efficacy and predictors for HbA1c reduction of sitagliptin in the treatment of Japanese type 2 diabetes

Author keywords

BMI; Dipeptidyl peptidase 4 (DPP 4) inhibitor; HbA1c; Sitagliptin

Indexed keywords

1,5 ANHYDROSORBITOL; GLUCOSE; HEMOGLOBIN A1C; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SITAGLIPTIN;

EID: 84355162099     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2011.10.011     Document Type: Article
Times cited : (62)

References (10)
  • 1
    • 34547863123 scopus 로고    scopus 로고
    • Efficiency and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin
    • for Stein P for the Sitagliptin 035 Study Group
    • Hermansen K., Kipnes M., Luo E., Fanurik D., Khatami H. Efficiency and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007, 9:737-745. for Stein P for the Sitagliptin 035 Study Group.
    • (2007) Diabetes Obes Metab , vol.9 , pp. 737-745
    • Hermansen, K.1    Kipnes, M.2    Luo, E.3    Fanurik, D.4    Khatami, H.5
  • 2
    • 77949387699 scopus 로고    scopus 로고
    • Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
    • Sitagliptin Study 024 Group
    • Seck T., Nauck M., Sheng D., Sunga S., Davies M.J., Stein P.P., et al. Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study. Int J Clin Pract 2010, 64:562-576. Sitagliptin Study 024 Group.
    • (2010) Int J Clin Pract , vol.64 , pp. 562-576
    • Seck, T.1    Nauck, M.2    Sheng, D.3    Sunga, S.4    Davies, M.J.5    Stein, P.P.6
  • 3
    • 79956315355 scopus 로고    scopus 로고
    • The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
    • Reasner C., Olansky L., Seck T.L., Williams-Herman D.E., Chen M., Terranella L., et al. The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus. Diabetes Obes Metab 2011, 13:644-652.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 644-652
    • Reasner, C.1    Olansky, L.2    Seck, T.L.3    Williams-Herman, D.E.4    Chen, M.5    Terranella, L.6
  • 4
    • 34547660561 scopus 로고    scopus 로고
    • Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes
    • for the Sitagliptin 036 Study Group
    • Goldstein B.J., Johnson J., Feinglos M.N., Williams-Herman D.E., Lunceford J.K. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007, 30:1979-1987. for the Sitagliptin 036 Study Group.
    • (2007) Diabetes Care , vol.30 , pp. 1979-1987
    • Goldstein, B.J.1    Johnson, J.2    Feinglos, M.N.3    Williams-Herman, D.E.4    Lunceford, J.K.5
  • 5
    • 39749184723 scopus 로고    scopus 로고
    • Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
    • Raz I., Chen Y., Wu M., Hussain S., Kaufman K.D., Amatruda J.M., et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008, 24:537-550.
    • (2008) Curr Med Res Opin , vol.24 , pp. 537-550
    • Raz, I.1    Chen, Y.2    Wu, M.3    Hussain, S.4    Kaufman, K.D.5    Amatruda, J.M.6
  • 6
    • 78751562877 scopus 로고    scopus 로고
    • Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes
    • Yoon K.H., Shockey G.R., Teng R., Golm G.T., Thakkar P.R., Meehan A.G., et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and pioglitazone on glycemic control and measures of β-cell function in patients with type 2 diabetes. Int J Clin Pract 2011, 65:154-164.
    • (2011) Int J Clin Pract , vol.65 , pp. 154-164
    • Yoon, K.H.1    Shockey, G.R.2    Teng, R.3    Golm, G.T.4    Thakkar, P.R.5    Meehan, A.G.6
  • 7
    • 77957741412 scopus 로고    scopus 로고
    • Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men
    • Aoki K., Masuda K., Miyazaki T., Togashi Y., Terauchi Y. Effects of miglitol, sitagliptin or their combination on plasma glucose, insulin and incretin levels in non-diabetic men. Endocr J 2010, 57:667-672.
    • (2010) Endocr J , vol.57 , pp. 667-672
    • Aoki, K.1    Masuda, K.2    Miyazaki, T.3    Togashi, Y.4    Terauchi, Y.5
  • 8
    • 41849099939 scopus 로고    scopus 로고
    • Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension
    • Mistry G.C., Maes A.L., Lasseter K.C., Davies M.J., Gottesdiener K.M., Wagner J.A., et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol 2008, 48:592-598.
    • (2008) J Clin Pharmacol , vol.48 , pp. 592-598
    • Mistry, G.C.1    Maes, A.L.2    Lasseter, K.C.3    Davies, M.J.4    Gottesdiener, K.M.5    Wagner, J.A.6
  • 9
    • 79956326006 scopus 로고    scopus 로고
    • Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials
    • Esposito K., Cozzolino D., Bellastella G., Maiorino M.I., Chiodini P., Ceriello A., et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011, 13:594-603.
    • (2011) Diabetes Obes Metab , vol.13 , pp. 594-603
    • Esposito, K.1    Cozzolino, D.2    Bellastella, G.3    Maiorino, M.I.4    Chiodini, P.5    Ceriello, A.6
  • 10
    • 79952310049 scopus 로고    scopus 로고
    • Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
    • Nauck M.A., Vardarli I., Deacon C.F., Holst J.J., Meier J.J. Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 2011, 54:10-18.
    • (2011) Diabetologia , vol.54 , pp. 10-18
    • Nauck, M.A.1    Vardarli, I.2    Deacon, C.F.3    Holst, J.J.4    Meier, J.J.5


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.